Evaluate the use of Early-Stage Follicular Lymphoma International ImmunoTherapy Registry and initial analysis plan to describe progression-free survival for patients with stage I-II follicular lymphoma treated with radiotherapy alone compared with radiotherapy plus immunotherapy.
Not Applicable
- Conditions
- Stage I-II low grade follicular lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
- Registration Number
- ACTRN12624000669594
- Lead Sponsor
- Peter MacCallum Cancer Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. Male or female, > 18 years of age.
2. Patients with histologically WHO grade 1, 2 or 3a FL.
3. Treated with curative intent RT to any dose
4. Intended to receive either no further treatment or adjuvant treatment containing anti-CD20 antibody therapy or other immunotherapy
5. Minimum follow up of 3 months from commencement of treatment.
Exclusion Criteria
1. Previous treatment for FL
2. Composite lymphoma
3. Previous diagnosis of lymphoma
4. Treated with wide-field RT (RT involving both sides of the diaphragm targeting uninvolved nodal sites)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method